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Interest in imiquimod (IMQ) fi  rst came from the 
observation that this imidazoquinoline exerts a 
profound activity against viral acanthomas that 
was originally explained by its IFN-  inducing 
capacity (1). When used topically for a  prolonged 
period of time, it can lead to the regression of 
certain virus-induced (e.g., genital warts [2] and 
molluscum contagiosum [3]) and other (e.g., 
basal cell carcinoma [BCC] [4, 5] and lentigo 
maligna [6]) skin neoplasms. IMQ exerts its 
biologic activity primarily by ligation of Toll-
like receptor (TLR) 7 (7) and, to a lesser extent, 
TLR8, both of which have been identifi  ed as 
natural receptors for single-stranded RNA 
(8, 9). Cell stimulation via TLR7 and TLR8 leads 
to downstream activation of NF-κB and other 
transcription factors (10, 11). Consequently, 
several genes encoding mediators and eff  ector 
molecules of the innate as well as the adap-
tive immune response are transcribed (12–14). 
  Because of their prominent expression of TLR7 
and TLR8, plasmacytoid DCs (pDCs) and my-
eloid DCs (mDCs) (15, 16), respectively, are 
therefore likely candidates for the initiation of 
the IMQ-induced host defense reaction. Other 
mechanisms explaining the antitumor activity 
of IMQ are also under discussion. These include 
(a) the reversal of CD4+ regulatory T cell function 
(17), (b) a TLR-independent immunostimu-
latory action of IMQ via adenosine receptor 
signaling (18), (c) direct (19) and indirect, via 
IFN-α (20), IMQ-induced proapoptotic eff  ects 
on tumor cells, and (d) an antiangiogenic ac-
tivity of IMQ, as shown in a mouse model of 
angiogenesis (21, 22).
In a recent study, our group investigated 
IMQ-induced tumor regression in mice and 
found not only a good clinical response of the 
tumors to the topically applied compound but 
also a direct correlation between IMQ-induced 
tumor regression and the density of DCs in the 
peritumoral tissue (23). Not infrequently, cancer 
cells in death were found in close contact with 
DCs, which was compatible with a tumoricidal 
property of the latter (24, 25). In this study, we 
sought to determine whether similar phenome-
nona also occur during IMQ treatment of human 
skin cancers and, if so, to unravel the mechanisms 
responsible for IMQ-induced tumor regression.
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Imiquimod (IMQ), a synthetic agonist to Toll-like receptor (TLR) 7, is being successfully used 
for the treatment of certain skin neoplasms, but the exact mechanisms by which this com-
pound induces tumor regression are not yet understood. While treating basal cell carcinoma 
(BCC) patients with topical IMQ, we detected, by immunohistochemistry, sizable numbers of 
both myeloid dendritic cells (mDCs) and plasmacytoid DCs (pDCs) within the infl  ammatory 
infi  ltrate. Surprisingly, peritumoral mDCs stained positive for perforin and granzyme B, 
whereas infi  ltrating pDCs expressed tumor necrosis factor–related apoptosis-inducing ligand 
(TRAIL). The biological relevance of this observation can be deduced from our further fi  nd-
ings that peripheral blood–derived CD11c+ mDCs acquired antiperforin and anti–granzyme 
B reactivity upon TLR7/8 stimulation and could use these molecules to effectively lyse major 
histocompatibility complex (MHC) class Ilo cancer cell lines. The same activation protocol led 
pDCs to kill MHC class I–bearing Jurkat cells in a TRAIL-dependent fashion. While suggesting 
that mDCs and pDCs are directly involved in the IMQ-induced destruction of BCC lesions, 
our data also add a new facet to the functional spectrum of DCs, ascribing to them a major 
role not only in the initiation but also in the effector phase of the immune response.
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RESULTS
Regression of BCC upon IMQ treatment
Seven patients with histopathologically confi  rmed superfi  cial 
BCC were treated with IMQ. After a treatment period of 
6 wk, we observed a complete clinical (Fig. 1) and histopatho-
logical response in all patients. No signs of recurrence were 
noted in any of the patients followed for at least 10 mo.
In accordance with a previous report (4), all patients de-
veloped, before tumor clearance, an infl  ammatory tissue re-
action at the site of IMQ application. It began as erythema 
after 2–3 d of treatment; became erosive during the second 
week (Fig. 1); appeared as crusting and, later, scaling plaques 
after 3–4 wk; and resolved completely after cessation of IMQ 
treatment. Systemic side eff  ects such as fl  u-like symptoms, 
lymphadenopathy, myalgia, or changes in laboratory values 
never occurred in any of our patients.
Emergence kinetics of leukocytic populations 
in the peritumoral infi  ltrate upon IMQ treatment
Biopsies from BCCs were obtained before, during, and after 
IMQ treatment and subjected to immunofl  uorescence analy-
sis using a broad panel of antibodies (Table I) to analyze, both 
quantitatively and qualitatively, the composition and kinet-
ics of the IMQ-induced infl  ammatory infi  ltrate. In untreated 
BCCs we found a sparse infi  ltrate, mainly consisting of T cells 
of the helper phenotype (Table II). Upon 2 wk of IMQ treat-
ment, a dramatic increase of CD8+ T cells and, to a much 
lesser extent, of CD4+ T cells was seen around tumor cell is-
lets (Table II). Fig. 2 (A and B) shows that, after 2 wk of topi-
cal IMQ treatment, BCC islets were surrounded and partly 
infi  ltrated by dendritically shaped cells exhibiting either the 
CD11c+/HLA-DR+ mDC (Fig. 2 A) or the CD123+/HLA-
DR+ pDC (Fig. 2 B) phenotype. This increase in infl  am-
matory-type mDCs and pDCs occurs at the expense of the 
resident DC populations of normal human skin (Langerhans 
cells and CD1c+ dermal DCs; Table II). Other constituents 
of the peritumoral infi  ltrate included (a) CD56+/CD94+ NK 
cells, (b) CD14+ mononuclear phagocytes, and (c) CD15+/
HLA-DR− neutrophils (Table II). In contrast, B cell, eosinophil, 
basophil, and mast cell counts displayed no major alterations 
upon IMQ treatment. At the end of treatment, when tumor 
clearance was achieved, the density of the various infi  ltrating 
leukocyte subpopulations was comparable to the values before 
IMQ application (Table II).
Detection of lytic molecules in the peritumoral tissue 
upon IMQ treatment
Analyzing the mechanisms of IMQ-induced tumor regres-
sion, we searched, by Tdt-mediated dUTP-biotin nick-end 
labeling (TUNEL) staining, for signs of apoptosis in IMQ- 
treated BCC lesions. Although only a few TUNEL+ tumor 
cells were detected in untreated BCCs (Fig. 2 C), the decrease 
Figure 1.  Complete regression of superfi  cial BCC after a 6-wk treat-
ment period with IMQ. IMQ topically applied fi  ve times a week for a period 
of 6 wk led to a local infl  ammatory response, which resulted in a complete 
clinical and histopathological tumor clearance in all patients treated. The 
clinical pictures are representative for all patients (n = 7) treated with IMQ.
Table I.  List of mAbs used in this study
Antibody specifi  city Clone (source of antibodies) Isotype
Staining experiments
BDCA-2 (FITC) AC144 (Miltenyi Biotec) mIgG1
CD1a (FITC) HI149 (BD Biosciences) mIgG1
CD1c (pur., biot.) M241 (Ancell) mIgG1
CD3 (FITC, PerCP) SK-7 (BD Biosciences) mIgG1
CD4 (pur.) SK-3 (BD Biosciences) mIgG1
CD8 (pur.) C8/144B (DakoCytomation) mIgG1
CD8 (allophycocyanin [APC]) B9.11 (Immunotech Coulter) mIgG1
CD11c (FITC) BU15 (Serotec) mIgG1
CD11c (PE, PE-Cy5) B-ly6 (BD Biosciences) mIgG1
CD14 (pur., FITC, PerCP) MϕP9 (BD Biosciences) mIgG2b
CD15 (FITC) 80H5 (Immunotech Coulter) mIgM
CD19 (pur., PerCP) SJ25C1 (BD Biosciences) mIgG1
CD45RA (pur.) L48 (BD Biosciences) mIgG1
CD56 (biot., PE-Cy5) B159 (BD Biosciences) mIgG1
CD83 (FITC) H15a (Immunotech Coulter) mIgG2b
CD94 (pur.) HP-3D9 (BD Biosciences) mIgG1
CD117 (c-kit, pur.) 95C3 (An Der Grub) mIgG1
CD123 (biot.) 9F5 (BD Biosciences) mIgG1
CD203c (PE) 97A6 (Immunotech Coulter) mIgG1
CD207 (pur.) DCGM4 (Immunotech Coulter) mIgG1
Fas ligand (pur.) NOK-1 (BD Biosciences) mIgG1
Granzyme B (pur.) GrB-7 (Monosan) mIgG2a
Granzyme B (PE) GB-11 (PeliCluster) mIgG1
HLA-DR (pur., FITC, APC) L243 (BD Biosciences) mIgG2a
IFN-α 225.2C (Chromaprobe) mIgG2b
iNOS (FITC) 6 (BD Biosciences) mIgG2a
MBP (pur.) BMK13 (Chemicon) mIgG1
Pancytokeratin (pur.) AE1 and AE3 (BioGenex) mIgG1
Perforin (pur.) dG9 (Abcam) mIgG2b
Perforin (FITC) δG9 (BD Biosciences) mIgG2b
TNF-α (FITC) MAb11 (BD Biosciences) mIgG1
TRAIL (pur.) 75402 (R&D Systems) mIgG1
TRAIL (neutralizing; pur.) 75411 (R&D Systems) mIgG1
TRAIL R1 (pur.) 69036 (R&D Systems) mIgG1
Cell-sorting experiments
CD3 (pur.) UCHT1 (Immunotech Coulter) mIgG1
CD16 (pur.) 3G8 (Immunotech Coulter) mIgG1
CD19 (pur.) J4.119 (Immunotech Coulter) mIgG1
CD34 (pur.) 581 (Immunotech Coulter) mIgG1
CD41 (pur.) SZ22 (Immunotech Coulter) mIgG1
CD56 (pur.) C218 (Immunotech Coulter) mIgG1
CD235a (pur.) 11E4B-7-6 (Immunotech Coulter) mIgG1
biot., biotinylated; MBP, eosinophil major basic protein; pur., purifi  ed.JEM VOL. 204, June 11, 2007  1443
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in pancytokeratin+ BCC cells after 2 wk of therapy was ac-
companied by a concomitant increase of TUNEL+ tumor 
cells (Fig. 2 D). One may therefore conclude that BCC re-
gression upon IMQ treatment is at least partly accomplished 
by apoptosis of tumor cells.
Based on the observation of IFN-α–induced tumor re-
gression (26) and tumor cell apoptosis (27), we searched for 
the presence of IFN-α–producing cells in IMQ-treated BCC 
biopsies and found  30% of all pDCs, but no other leuko-
cytes, to exhibit anti–IFN-α staining (Fig. 2 E). It is therefore 
not unreasonable to assume that IMQ-activated pDCs con-
tribute to BCC apoptosis by IFN-α production.
In addition to IFN-α–induced apoptotic events, perforin/
granzyme-based and death receptor ligand–mediated cancer 
cell lysis are the immune system’s major tumoricidal eff  ector 
mechanisms. When we analyzed BCC biopsies before, during, 
and after IMQ treatment for the expression of lytic mole-
cules, we could hardly detect any expression of Fas ligand 
(Fig. 2 F). In contrast, we observed a considerable up-regulation 
of perforin, granzyme B, and TNF-related apoptosis-inducing 
ligand (TRAIL) on infi  ltrating cells after 2 wk of IMQ treat-
ment when compared with the low baseline levels of un-
treated BCCs (Fig. 2 F).
The majority of anti-TRAIL reactivity was observed on 
T cells (Fig. 3 A), but CD11c+ mDCs, CD123+ pDCs, and 
CD14+ mononuclear phagocytes also expressed this molecule 
(Fig. 3, A and B). The biologic importance of this fi  nding is 
underscored by the further observation that tumor cells of 
untreated (Fig. 3 C) and IMQ-treated (Fig. 3 D) BCC lesions 
were positive for TRAIL receptor 1 (TRAIL R1) and sur-
rounded by a dense rim of CD123+ cells (Fig. 3 D). Anti-
TRAIL R2, R3, and R4 stainings yielded negative results 
(not depicted).
Somewhat to our surprise, we found that only a few T cells 
and NK cells displayed antiperforin and anti–granzyme B 
staining and that CD3−CD56−HLA-DR+ cells were the main 
source of these lytic molecules (Fig. 4, A and C). Additional 
phenotyping revealed that these cells were CD11c+ (Fig. 
4, B and D) and lacked lineage markers such as CD3, CD56, 
CD14, CD15, or CD19, as well as CD1a and CD207, thus 
corresponding to mDCs. Similar to what has been observed 
in untreated psoriatic skin lesions (28), CD11c+/HLA-DR+ 
DCs in IMQ-treated BCC lesions were also found to re-
act with antibodies against inducible NO synthase (iNOS) 
and TNF-α (Fig. 4 E). At least phenotypically, these cells 
therefore corresponded to TNF-α– and iNOS-  producing 
DCs, an mDC population possibly involved in innate immune 
  defense against bacteria (29). In contrast to infi  ltrating pDCs 
(Fig. S1 A, available at http://www.jem.org/cgi/content/full/
jem.20070021/DC1), the vast majority of CD11c+/HLA-
DR+ DCs displayed the maturation marker CD83 (Fig. S1 B). 
As it was quite unexpected not to fi  nd cytotoxic T cells 
Table II.  Number of leukocytes occurring in BCCs before, after 2 wk, and at the end of IMQ treatment
Cell type Antigens Epidermis/dermis Untreated BCCs 2 wk IMQ 6 wk IMQ
T helper cells CD4+/CD3+ epidermis (cells/mm) 
dermis (cells/mm2)
1.8 ± 2
98.2 ± 64.4
3.3 ± 3.3 
164 ± 60.6
1.4 ± 1.8 
99 ± 56.8
Cytotoxic T cells CD8+/CD3+ epidermis (cells/mm) 
dermis (cells/mm2)
1.4 ± 0.9 
55.7 ± 31.1
5.5 ± 2.6 
236.6 ± 61.4
3.7±3.4 
63.1±35.3
NK cells CD56+/CD94+ epidermis (cells/mm) 
dermis (cells/mm2)
0 
3 ± 2.2
0.7 ± 1.3 
46.8 ± 19
0 
10.1 ± 10.7
Langerhans cells CD207+/CD1a+ epidermis (cells/mm) 
dermis (cells/mm2)
9 ± 4.2 
6.2 ± 3.6
3.6 ± 1.7 
6.7 ± 4.9
8.3 ± 5.2 
5.1 ± 4.7
CD11c+ mDCs CD11c+/HLA-DR+ epidermis (cells/mm) 
dermis (cells/mm2)
0 
25.5 ± 4.2
0 
58.4 ± 14.6
0 
22.9 ± 4.8
CD1c+ mDCs CD1c+/HLA-DR+ epidermis (cells/mm) 
dermis (cells/mm2)
0.7 ± 1.3 
55.2 ± 29.7
0.3 ± 0.5 
16.3 ± 7.4
0.3 ± 0.4 
24.1 ± 12.7
Phagocytes CD14+ epidermis (cells/mm) 
dermis (cells/mm2)
1.4 ± 3.8 
21.2 ± 15.2
2.4 ± 3.6 
47.6 ± 6.1
1.3 ± 3 
35.1 ± 12.7
pDCs CD123+/ CD45RA+ epidermis (cells/mm) 
dermis (cells/mm2)
0.2 ± 0.4 
9.9 ± 12.1
0 
54.7 ± 6.5
0 
17.1 ± 8.8
Neutrophils CD15+/HLA-DR− epidermis (cells/mm) 
dermis (cells/mm2)
0 
7.8 ± 8.9
0 
62.1 ± 14.3
0 
15.4 ± 13
Eosinophils MBP+ epidermis (cells/mm) 
dermis (cells/mm2)
0 
0
0 
2.1 ± 3.3
0 
0.5 ± 0.9
Basophils CD203c+ epidermis (cells/mm) 
dermis (cells/mm2)
0 
0
0 
0
0 
0
Mast cells cKit+ epidermis (cells/mm) 
dermis (cells/mm2)
0 
14.3 ± 13.5
0 
13.3 ± 2.9
0 
10.4 ± 11.7
B cells CD19+ epidermis (cells/mm) 
dermis (cells/mm2)
0 
3.2 ± 4.6
0 
2.8 ± 5.6
0 
1.1 ± 1.5
Cells were visualized using the indicated markers and were evaluated by immunofl  uorescence analysis. Numbers in bold indicate means ± SE of the mean of cells counted in 
BCC lesions before, after 2 wk, and after 6 wk of IMQ treatment. MBP, eosinophil major basic protein.1444  TUMORICIDAL FUNCTION OF ACTIVATED DENDRITIC CELLS | Stary et al.
and/or NK cells, but instead to find DCs containing per-
forin and granzyme B, we compared immuno  fl  uorescence 
triple stainings of IMQ-treated BCCs with those of allergic 
contact dermatitis, a disease in which perforin- and gran-
zyme B–containing T cells have been previously described 
(30). In contrast to IMQ-treated BCC lesions in which most 
perforin- and granzyme B–positive cells were CD3− as 
well as CD8−, antiperforin and anti–granzyme B reactivity 
in allergic contact dermatitis was mainly restricted to T cells 
(Fig. S1, C–F).
Detection of perforin and granzyme B in mDCs 
upon TLR7 and TLR8 stimulation and of TRAIL 
on pDCs upon TLR7 stimulation
To determine the biological signifi  cance of anti-TRAIL and 
antiperforin/anti–granzyme B staining of DCs in IMQ-
treated BCC lesions, we decided, for quantitative reasons, to 
work with DCs isolated from peripheral blood rather than 
from these skin lesions. Using the protocol described in 
Materials and methods, we routinely obtained mDC and 
pDC populations of 93–99% (mean = 97%) purity. By FACS 
analysis, these cells were HLA-DR+, expressed either high 
levels of CD11c or BDCA-2, and lacked the lineage markers 
CD3, CD56, CD14, and CD19 (Fig. 5 A). None of the lytic 
molecules searched for were detected on freshly isolated 
mDCs. In contrast, stimulation of purifi  ed peripheral blood–
derived mDCs with TLR7 and TLR8 ligands, but not with 
the vehicle control, led to the intracellular expression of per-
forin and granzyme B in  10–15% of these cells (Fig. 5, B 
and C). Expression of TRAIL was not detectable on mDCs 
after stimulation with TLR7/8 ligands (Fig. 5 D).
Unstimulated pDCs abundantly contained granzyme B 
within their cytoplasm (Fig. 5 E). After 12 h of stimulation 
with ligands to TLR7 and TLR7/8, but not with the vehicle 
control or the TLR8 ligand alone, the intracellular expres-
sion of granzyme B in pDCs had decreased. (Fig. 5, E and F). 
This is consistent with the previous fi  nding of pDCs express-
ing TLR7 but not TLR8 (15). In contrast to mDCs, TLR7/8 
Figure 2.  Induction of tumor cell apoptosis is accompanied by 
peritumoral accumulation of DCs and up-regulation of lytic 
  molecules on infl  ammatory cells. (A and B) Immunofl  uorescence triple 
labeling of cryostat sections of IMQ-treated BCC lesions with antipan-
cytokeratin (TRITC), anti–HLA-DR (FITC), and either (A) anti-CD11c (APC) or 
(B) anti-CD123 (Cy5) revealed a close proximity of both DC populations 
with tumor cells. Arrows indicate double-positive DCs. (C) Untreated 
BCCs and (D) BCCs after 2 wk of IMQ treatment were stained with an 
antipancytokeratin antibody (TRITC) and TUNEL staining (FITC). Note 
the double-positive tumor cells occurring after 2 wk of IMQ treatment 
(arrows). The pictures are representative for all evaluated biopsies. The 
dotted lines point out the margins of BCCs. (E) Identifi  cation of IFN-α–
producing pDCs in 2-wk–treated BCCs by triple stainings with anti–
IFN-α (TRITC), anti–HLA-DR (FITC), and anti-CD123 (Cy5) mAbs. The 
arrow indicates a triple-positive cell. (F) Quantitative analysis of lytic 
molecules expressed by infl  ammatory cells of the peritumoral infi  ltrate. 
Immunofl  uorescence single stainings were performed using antiperforin, 
anti–granzyme B, anti-Fas ligand, and anti-TRAIL antibodies (all TRITC). 
Data are given as absolute numbers of positive cells ± SEM for the indi-
cated markers.
Figure 3.  Upon IMQ treatment, TRAIL R1+ BCC islets are sur-
rounded by TRAIL-expressing pDCs. (A) Detailed quantitative in situ 
analysis of the expression pattern of TRAIL on leukocytes before, during, 
and after IMQ treatment was performed by immunofl  uorescence double 
stainings with an anti-TRAIL mAb and lineage markers in all patients 
treated. The data are given as absolute numbers of double-positive 
cells ± SEM. (B) A representative view of anti-CD123 (FITC), anti–HLA-DR 
(APC), and anti-TRAIL (TRITC) triple stainings of a BCC lesion after 2 wk of 
IMQ treatment identifi  es pDCs as TRAIL-expressing cells. Immunofl  uores-
cence triple labeling of (C) untreated and (D) IMQ-treated BCCs with 
antipancytokeratin (TRITC), anti-TRAIL R1 (A488), and anti-CD123 
(Cy5) reveals TRAIL R1+ BCC cells (C and D) surrounded by CD123+ 
cells (arrows; D).JEM VOL. 204, June 11, 2007  1445
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agonists induced up-regulation of TRAIL on the surface of 
pDCs (Fig. 5 G). Similar to the pretreatment situation, the 
cell populations stimulated with TLR7/8 agonists for 12 h 
failed to express CD3 and CD56, strongly arguing against the 
possibility of the involvement of T cells and/or NK cells. 
These fi  ndings indicate that, upon stimulation with TLR7/8 
agonists, mDCs and pDCs from peripheral blood acquire the 
phenotype of mDCs and pDCs found in the peritumoral tis-
sue of IMQ-treated BCC lesions.
mDCs release perforin and granzyme B upon 
TLR7 and TLR8 stimulation
The cytotoxic eff  ect of the perforin–granzyme B pathway 
is only functional if the cytotoxic proteins are degranulated 
and come into contact with target cells. To reveal possible 
cytotoxic functions of perforin- and granzyme B–expressing 
TLR7/8-stimulated DCs, we analyzed perforin and gran-
zyme B levels in the supernatants of sorted DCs after TLR7 
and TLR8 ligation by ELISA. The viability of DCs was 
controlled by annexin V (fl  ow cytometry) and trypan blue 
stainings (counting chamber) and exceeded 90% before and 
after cultures. Supernatants of PMA/ionomycin-stimulated, 
negatively selected T cells served as positive controls. We 
observed a substantial release of perforin and granzyme B 
Figure 4.  IMQ treatment induces the up-regulation of perforin 
and granzyme B on mDCs in the peritumoral infi  ltrate. A detailed 
quantitative analysis of the expression pattern of (A) perforin and 
(C) granzyme B on leukocytes before, during, and after IMQ treatment 
was performed by immunofl  uorescence double stainings with antibodies 
against the indicated lytic molecules and lineage markers in all seven 
treated patients. The data are given as absolute numbers of double-positive 
cells ± SEM. Representative pictures of immunofluorescence triple 
stainings with anti-CD11c, anti–HLA-DR, and (B) antiperforin or (D) anti–
granzyme B mAbs of the peritumoral infi  ltrate after 2 wk of treatment 
with IMQ. (E) Triple immunofl  uorescence labeling of BCCs upon IMQ 
treatment with anti-CD11c (PE), anti–HLA-DR (APC), and anti-iNOS (FITC) 
or anti–TNF-α (FITC) mAbs identifi  es iNOS and TNF-α to be produced by 
CD11c+HLA-DR+ cells (arrows).
Figure 5.  Peripheral blood–derived DCs express lytic molecules 
after TLR7/8 stimulation. (A) Characterization of isolated peripheral 
blood–derived pDCs and mDCs as HLA-DR+BDCA-2+ and HLA-
DR+CD11c+, respectively, and lineage-negative cell populations by fl  ow 
cytometry. (B and C) Analysis of intracellular expression levels of perforin 
and granzyme B of isolated mDCs before and after culture with TLR7/8 
agonists by fl  ow cytometry. (B) Representative dot plots of mDCs show 
double-positive cells for perforin (FITC) and granzyme B (PE) after stimu-
lation with TLR7, TLR8, and TLR7/8 agonists. (C) Quantitative analysis of 
granzyme B+ and perforin+ mDCs. Data are given as mean percentages of 
perforin- or granzyme B–positive mDCs ± SEM from three independent 
experiments. (D) Freshly isolated and TLR7/8-stimulated mDCs do not 
display membrane-bound TRAIL (A488). Representative histogram plots 
from three independent experiments show the anti-TRAIL reactivity (bold 
line) and the matching isotype control (dashed line). (E and F) Determina-
tion of intracellular expression levels of perforin and granzyme B on 
isolated pDCs before and after stimulation with TLR agonists. (E) Repre-
sentative dot plots of pDCs show a decrease of granzyme B–positive cells 
after stimulation with TLR7 and TLR7/8 agonists. (F) Quantitative analysis 
of pDCs expressing perforin and granzyme B. Data are given as mean 
percentages of perforin- and granzyme B–positive cells ± SEM from 
three independent experiments. (G) TLR7/8-stimulated, but not freshly 
isolated, pDCs display membrane-bound TRAIL (A488). Representative 
histogram plots from three different experiments show the anti-TRAIL 
reactivity (bold line) and the matching isotype control (dashed line). 
Dead cells were excluded by gating out propidium iodide–positive cells in 
all experiments.1446  TUMORICIDAL FUNCTION OF ACTIVATED DENDRITIC CELLS | Stary et al.
after stimulation of mDCs with TLR7 and TLR8 ligands, in 
contrast to the vehicle control (Fig. 6, A and B). We de-
tected granzyme B in the supernatants of pDCs after TLR7 
and TLR7/8 ligation but not after TLR8 ligation alone or 
vehicle control (Fig. 6 B), which was consistent with our 
FACS data described in the previous section. Perforin could 
not be detected at any setting in the supernatant of pDCs 
(Fig. 6 A). These data demonstrate that mDCs and pDCs 
can be activated to release lytic molecules in a biologically 
relevant fashion.
TLR7/8-stimulated mDCs and pDCs become killer cells: 
involvement of different cytotoxic pathways
To evaluate the functional signifi   cance of lytic molecules 
expressed by DCs after TLR7 and TLR8 ligation, we per-
formed cytotoxicity assays with purifi  ed peripheral blood–de-
rived mDCs and pDCs as eff  ector cells, and perforin-sensitive 
K562 (Fig. S2 A, available at http://www.jem.org/cgi/
content/full/jem.20070021/DC1) and TRAIL-sensitive Jurkat 
cell lines (31) as target cells. Although freshly isolated mDCs 
hardly displayed any cytotoxic activity against K562 and Jur-
kat cells, mDCs stimulated with TLR7/8 agonists eff  ectively 
lysed K562 but not Jurkat cells (Fig. 7 A). We observed the 
opposite eff  ect in pDCs, in that they exhibited substantial 
cytotoxic activity against Jurkat and not K562 cells after 
TLR7/8 stimulation, but not when unstimulated (Fig. 7 B). 
This diverse killing behavior indicated distinct mechanisms 
operative in DC-mediated cytotoxicity after stimulation with 
TLR7/8 ligands. To investigate the diff  erent cytotoxic path-
ways in greater detail, we performed inhibition experiments 
with (a) concanamycin A, a specifi  c inhibitor of the perforin-
based cytotoxic pathway (32), (b) a neutralizing anti-TRAIL 
antibody to block TRAIL-mediated killing, and (c) a neutral-
izing anti-Fas ligand antibody to inhibit Fas-induced killing. 
As shown in Fig. 7 C, coincubation of TLR7/8-stimulated 
mDCs and K562 in the presence of concanamycin A led to 
a complete disappearance of the specifi  c lysis, whereas anti-
TRAIL and anti-Fas ligand antibodies had no eff  ect on the 
mDC-mediated cytotoxicity. On the other hand, preincuba-
tion of TLR7/8-stimulated pDCs with an inhibitory anti-
TRAIL antibody essentially abolished the pDC cytotoxicity 
against Jurkat cells (Fig. 7 D); the specifi  city of this inhibition 
is also documented by the failure of concanamycin A and 
anti-Fas ligand antibodies to block the killing of Jurkat cells 
by TLR7/8-activated pDCs. To exclude the theoretical pos-
sibility of contaminating NK/NKT cells exhibiting cytotoxic 
Figure 6.  Secretion of perforin and granzyme B by mDCs upon 
TLR7 and TLR8 stimulation. (A) Perforin and (B) granzyme B protein 
levels were determined by ELISA in media conditioned by purifi  ed blood–
derived mDCs and pDCs after 12 h of stimulation with TLR7 and TLR8 
agonists. Media conditioned by 12-h PMA/ionomycin-stimulated T cells 
were used as positive controls. Data are given as means ± SEM from two 
independent experiments with 2 × 105 cells in each setting.
Figure 7.  Tumoricidal activity of blood-derived mDCs and pDCs 
after stimulation with TLR7/8 agonists. Unstimulated, TLR7/8-
stimulated, or vehicle-stimulated (A) mDCs and (B) pDCs were cultured 
with K562 or Jurkat as target cells for a conventional 2-h europium-TDA 
release assay at the indicated effector/target cell ratios. Data represent the 
means of triplicate wells ± SEM from two independent experiments. 
(C and D) For inhibition of different cytotoxicity-inducing pathways, 12-h 
TLR7/8-stimulated mDCs and pDCs as effector cells were preincubated 
with 100 nM concanamycin A for 120 min, 5 μg/ml anti-TRAIL for 
30 min, 5 μg/ml anti-Fas ligand for 30 min, or 5 μg/ml of an IgG1 isotype 
for 30 min. Target cells were (C) K562 for TLR7/8-stimulated mDCs and 
(D) Jurkat for TLR7/8-stimulated pDCs. Cytotoxicity was determined by a 
2-h europium-TDA release assay at the indicated effector/target cell 
ratios. Data represent the means of triplicate wells ± SEM from two 
independent experiments.JEM VOL. 204, June 11, 2007  1447
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activity within isolated DC populations, we performed cyto-
toxicity assays with eff  ector cells consisting of irrelevant fi  ller 
cells (i.e., A431) containing titrated numbers of NK cells. In 
a setting of 7% NK cells titrated into A431 as fi  ller cells, we 
observed a 10% cytotoxic activity against K562 and Jurkat 
(Fig. S2 B), which represented less than half of the mDC-
mediated killing and less than one third of pDC-mediated 
cytotoxicity. In addition, NK cells killed K562 and Jurkat 
cells with a comparable intensity and did not show selective 
killing like mDCs and pDCs. As NK cells and T cells never 
accounted for >1% within purifi  ed DC populations (Fig. 
5 A), these experiments strongly argue against contaminating 
cells being even partly responsible for the cytotoxic activity 
of the DC populations.
D  I  S  C  U  S  S  I  O  N 
IMQ is now an established therapeutic option in the treat-
ment of certain skin neoplasms such as genital warts (2), ac-
tinic keratoses (33), and BCCs (4, 5). In BCCs, cure rates are 
similar to those achieved with other therapeutic procedures 
(34, 35). Our study confi  rms these observations.
After binding to and signaling through TLR7 (7), IMQ 
leads to up-regulation of cytokines with growth-inhibitory 
(e.g., IFN-α) and/or proinfl  ammatory (e.g., TNF-α, IL-1, 
and IL-6) properties (1, 36). TLR-independent mechanisms, 
operating directly by induction of apoptosis (19) and/or indi-
rectly by adenosine receptor signaling (18), could also con-
tribute to the clinically observed tumor regression. Even 
though the IMQ-induced regression pattern of skin cancers 
shows no signs of T cell memory, evidence exists that CD8+ 
T cells are abundantly present in the infl  ammatory infi  ltrate 
of IMQ-treated skin cancers (12, 14). A role for NK cells has 
also been claimed (37). To address the involvement of cellu-
lar cytotoxicity in IMQ-induced tumor regression, in this 
study we searched for the expression of lytic molecules on/in 
diff  erent cell populations forming this infi  ltrate.
As opposed to the pretreatment situation, we detected 
sizable numbers of perforin/granzyme B–positive cells, as 
well as TRAIL-expressing cells, after 2 wk of IMQ treat-
ment. Interestingly, we observed that the majority of CD8+ 
T cells and CD56+ NK cells, which together formed a major 
portion of the IMQ-induced infi  ltrate, were largely devoid 
of antiperforin and anti–granzyme B reactivity. The reasons 
for this fi  nding are not entirely clear. One could argue that 
CD8+ T cells and NK cells are simply bystander cells within 
the infl  ammatory infi  ltrate and are not concerned with cyto-
toxic eff  ector functions. It is also conceivable that CD8+ 
T cells discharge their cytotoxic granules directly after migra-
tion into the peritumoral tissue; after 2 wk of IMQ treat-
ment, the time point we had chosen for taking the biopsies, 
these granules would therefore no longer be detectable 
within their cytoplasm. We cannot defi  nitively exclude this 
possibility. The occurrence of staining artifacts is unlikely, as 
we detected perforin- and granzyme B–positive T cells in 
skin biopsies of allergic contact eczema (Fig. S1, C and E). 
To our surprise, double and triple labeling of IMQ treated 
BCC sections revealed perforin and granzyme B to be ex-
pressed predominantly by lineage-negative CD11c+/HLA-
DR+ mDCs. On the other hand, TRAIL, a molecule directly 
involved in tumor cell killing by binding to its corresponding 
death receptors (38–40), was expressed on several cell types, 
including pDCs. We sought to better characterize the mDC 
subset expressing cytotoxic molecules in situ and found that 
they coexpress TNF-α and iNOS, two proinfl  ammatory 
mediators with antitumor activity (41, 42). Thus, these cells 
corresponded to TNF-α– and iNOS-producing DCs, which 
were shown to originate from blood-derived monocytes (43) 
and exhibit eff  ector functions in bacterial infections in mice 
(29) and to correlate with disease activity in psoriasis in 
humans (28).
We were not able to isolate DCs from IMQ-treated BCC 
lesions in numbers that would have suffi   ced to conduct 
meaningful functional experiments. We therefore decided 
to test the functional relevance of our immunostaining re-
sults in studies with peripheral blood–derived mDCs and 
pDCs stimulated with TLR7 and TLR8 agonists. When 
activated in vitro with such compounds, peripheral blood–
derived mDCs not only expressed and released perforin 
and granzyme B but also exhibited substantial cytotoxicity 
against MHC class I–negative (K562) but not MHC class 
I–positive (Jurkat) tumor cell lines. This lytic activity was 
abolished by pretreatment of eff  ector cells with concana-
mycin A, an inhibitor of perforin-mediated cytotoxicity. 
To rule out the possibility that T cells and/or NK/NKT 
cells would contaminate the mDC eff  ector cell population, 
we analyzed purifi  ed DCs of the peripheral blood by FACS 
stainings and by real-time PCR. Results obtained showed 
that these cells lacked all lineage markers at the protein level 
(Fig. 5 A) and were devoid of CD3ε transcripts (unpub-
lished data). We also titrated CD56+ cells into a population 
of nonfunctional fi  ller cells and found that the lytic capacity 
of this cell mixture was considerably lower than that of 
  purifi  ed TLR7/8-activated DCs, even when numbers of 
CD56+ NK cells were greater than the peak levels of all 
lineage−CD11c− cells ever encountered in our mDC prep-
arations (Fig. S2 B). Evidence for a direct cytotoxic poten-
tial of mDCs has also been presented by other investigators, 
but their fi  ndings diff  er from ours with regard to the acti-
vation status of the DCs and the type of lytic molecules 
involved (24, 44–48).
The emergence of pDCs in the peritumoral tissue of 
IMQ-treated skin cancers has been demonstrated in mice 
(23) and in humans (49). We confi  rmed the occurrence of 
IFN-α–producing pDCs in the peritumoral infi  ltrate during 
IMQ treatment. As IFN-α induces cytotoxic molecules on 
NK cells (50) and T cells (51), pDCs may indirectly contrib-
ute to the elimination of tumor cells. In this study, we asked 
whether pDCs could directly acquire eff  ector functions via 
up-regulation of cytotoxic molecules and, thus, play an active 
role in tumor clearance. In contrast to mDCs, pDCs occur-
ring within the peritumoral infi  ltrate expressed neither perfo-
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because unstimulated pDCs from peripheral blood clearly 
displayed intracellular anti–granzyme B (Fig. 5 E) (52, 53). 
Our further observation that pDC expression levels of gran-
zyme B are continuously decreasing upon TLR7 ligation may 
be an explanation for the results of our in situ stainings. In any 
event, granzyme B does not seem to contribute to the antitumor 
activity of pDCs, as inhibition of the perforin/granzyme B–
mediated cytotoxic pathway of TLR7/8-stimulated pDCs 
had no eff  ect on the cytotoxic activity of these cells. The 
physiological role of granzyme B in pDCs therefore remains 
to be established.
On the basis of our fi  ndings that pDCs occurring in the 
IMQ-induced infi  ltrate expressed TRAIL and that TLR7-
stimulated peripheral blood–derived pDCs displayed TRAIL 
on their surface and used this molecule for cytotoxic pur-
poses, we would like to propose that pDCs have the potential 
to act as anticancer eff  ector cells. Our results confi  rm and 
  extend observations by others demonstrating the TRAIL-
mediated cytotoxicity of pDCs after stimulation by infl  uenza 
virus or TLR agonists (25).
The biological importance of our fi  ndings was underlined 
by the observation that IMQ-treated BCC cells, surrounded 
by CD123+ pDCs, are TRAIL 1 (DR4)–positive (Fig. 3 D) 
and express only negligible amounts of MHC class I mole-
cules in situ (unpublished data). Even though we are aware of 
the fact that TLR7/8-stimulated DCs from peripheral blood 
are not necessarily equivalent to DCs that accumulate in the 
skin in response to TLR activation, our data suggest that per-
forin/granzyme B–bearing cytotoxic mDCs and TRAIL-
  expressing pDCs participate in IMQ-induced tumor regression 
by MHC class I–independent and death receptor–dependent 
killing of BCC cells, respectively. This does not exclude the 
possibility that other eff  ector molecules (e.g., TNF-α) are also 
involved in this process.
Many questions remain to be resolved. To begin with, it 
has to be determined whether all DCs or only subpopulations 
thereof can be transformed into eff  ector cells upon appropri-
ate stimulation. Although we did not fi  nd NKG2D, CD94, 
CD16, or CD56 to be expressed on cytotoxic mDCs or pDCs 
before or after TLR7/8 stimulation (unpublished data), the 
relationship of human DCs described in our study to the 
newly described IFN-producing killer DCs in mice (54, 55) 
has to be defi  ned. It also needs to be clarifi  ed whether nat-
ural TLR7/8 ligands (viral single-stranded RNA) or stimuli 
other than TLR7/8 agonists can endow DCs with lytic prop-
erties, which signaling cascades are involved in this process, 
and whether tumor cells, by an as of yet unknown recog-
nition process, are triggering the release of cytotoxic gran-
ules by activated DCs. All of this information is required to 
devise strategies for the use of cytotoxic DCs as tools in anti-
cancer immunotherapy.
Finally, it will be of great interest to determine whether DC 
cytotoxicity ever occurs in the course of pathophysiological 
DC-driven immune responses. If so, the attractive possibility 
exists that DCs may use this eff  ector mechanism to down-
  regulate the immune reactions that they initiate themselves.
MATERIALS AND METHODS
Patients and tissue material. Seven patients with histologically confi  rmed 
superfi  cial BCC (three females and four males; mean age = 78.3 ± 8.2) were 
enrolled in the study after giving their written informed consent. BCCs were 
located on the head (n = 2), the neck (n = 2), and the back (n = 3). None 
of the patients were immunosuppressed or had any dermatological disease 
that could exacerbate upon IMQ (Aldara; 3M Pharmaceuticals) treatment. 
BCCs included in this study were therapy naive and did not receive any 
BCC-specifi  c therapy (e.g., photodynamic therapy, 5-fl  uorouracil, or IFN-α) 
before this study.
Patients received a once daily, fi  ve-times-a-week dosing regimen of 
IMQ 5% cream for 6 wk, according to the offi   cial treatment guidelines 
  approved for BCC. The cream was applied as a thin layer without occlusion 
overnight exactly on the BCC sites. Safety and effi   cacy  were  clinically 
  monitored weekly and by blood examinations at weeks 3 and 6. After 6 wk 
of treatment, response rates were determined by clinical examination 
and histological analysis of a punch biopsy taken from formerly aff  ected 
BCC sites.
For immunofl  uorescence analysis, 4-mm punch biopsies were taken un-
der local anesthesia (1% lidocaine) from untreated BCCs after 2 wk of IMQ 
treatment, when the clinical signs of infl  ammation were strongest, and after 
6 wk of IMQ therapy at the treatment endpoint. The biopsies were embedded 
in optimum cutting tissue compound (Tissue-Tek; Sakura Finetek), snap-
frozen in liquid nitrogen, and stored at –80°C until further processing.
Studies involving patient material were performed according to the 
Declaration of Helsinki. Biopsies were routinely taken from every patient for 
diagnostic purposes, followed by an informed consent about a possible scien-
tifi  c use of the data obtained as recommended by the local ethics committee 
(Federal Academic Hospital Feldkirch).
Immunofl  uorescence  staining. Single and multicolor immunofl  uores-
cence staining procedures were performed as previously described (56). The 
mAbs used in this study and their sources are shown in Table I.
Apoptotic cells were detected using a kit from Roche Molecular Bio-
chemicals to visualize DNA breaks as TUNEL+, according to the manufac-
turer’s guidelines. After blocking with normal mouse serum for 20 min to 
diminish background staining, sections were counterstained with a purifi  ed 
antipancytokeratin mAb overnight at 4°C. Purifi  ed antibody binding was 
visualized by incubating the sections with rhodamine (TRITC)-conjugated 
Affi   niPure F(ab′)2 fragment goat anti–mouse IgG (H+L). The evaluation of 
immunofl  uorescence results was performed as previously described (56). In 
brief, biopsy specimens were read in a blinded fashion by two   independent 
investigators with a mean observer coeffi   cient <10%. Labeled cells were 
enumerated per visual fi  eld and expressed as the number of cells per millimeter/
basement membrane epidermis and millimeter2 dermis ± SEM.
Cell preparations from peripheral blood. Peripheral blood samples 
were purchased as buff  y coats from the Vienna Red Cross Center. DCs were 
isolated as follows: PBMCs were obtained by Ficoll-Plaque density gradient 
centrifugation (Histopaque-1077; Sigma-Aldrich) and depleted of T cells, 
B cells, NK cells, hemopoietic stem cells, monocytes, platelets, and erythro-
cytes by anti-CD3/CD19/CD56/CD34/CD14/CD16/CD41/CD235a 
(3 μg/ml each) immunolabeling and anti–mouse IgG immunomagnetic deple-
tion (MACS; Miltenyi Biotec). The remaining cell fraction was then divided 
into mDCs and pDCs by positive selection using anti-CD1c and, thereafter, 
anti-CD304 (BDCA-4) microbeads (MACS). The purity of isolated DC popu-
lations was 93–99%, as determined by fl  ow cytometric analysis (FACScan; BD 
Biosciences) with either anti-CD11c/HLA-DR or anti-CD303 (BDCA-2)/
HLA-DR stainings. None of the other leukocyte subpopulations tested 
  individually (T cells, B cells, NK cells, and monocytes) accounted for > 1% 
of the sorted cell population. T cells were prepared as a positive control 
for the analysis of the perforin and granzyme B release by negative selec-
tion from PBMCs using anti-CD11c/CD14/CD16/CD19/CD34/CD41/
CD56/CD123/CD235a (3 μg/ml each) immunolabeling and anti–mouse 
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for cytotoxicity assays were separated by anti-CD56 (3 μg/ml each) immu-
nolabeling and anti–mouse IgG immunomagnetic selection after T cell de-
pletion (MACS). The purity of T cells and NK cells was >99%, as determined 
by FACS analysis.
DC stimulation with TLR agonists. Synthetic agonists to TLR7 (3M-
001), TLR8 (3M-002), TLR7/8 (3M-003), and an inactive small molecule 
TLR7/8 analogue that served as a negative control (3M-006) were provided 
by R.L. Miller (3M Pharmaceuticals, St. Paul, MN). Isolated mDCs and 
pDCs were washed and resuspended in RPMI 1640 medium (Invitrogen) 
supplemented with heat-inactivated 10% FCS (Invitrogen) and 1% penicillin/
streptomycin (Invitrogen) and cultured with 4 μM 3M-001, 3M-002, 
3M-003, or 3M-006 for 12 h at 2 × 106 cells/ml in 0.25 ml in 96-well plates 
or 0.5 ml in 48-well plates. Viability of the cells was measured with trypan 
blue and annexin V (BD Biosciences) before and after cultures, according to 
the manufacturer’s instructions. Cells were analyzed by FACS stainings for 
detection of lytic molecules or used as eff  ector cells in cytotoxicity assays. 
Media conditioned by DC subsets were collected and stored at −20°C for 
further analysis.
Flow cytometry. To analyze lytic molecules on blood-derived DCs, we 
performed intra- and extracellular FACS stainings of isolated DC popu-
lations before and after culture with TLR agonists. After staining of DC 
populations with anti–BDCA-2 (Miltenyi Biotec) or anti-CD11c (BD Bio-
sciences) mAbs, cells were fi  xed and permeabilized with a cell permeabili-
zation kit (An Der Grub), according to the manufacturer’s instructions for 
intracellular protein detection. Cells were incubated with antiperforin FITC 
(BD Biosciences) and anti–granzyme B PE (PeliCluster; Sanquin) antibodies. 
Surface TRAIL expression was visualized by staining with an anti-TRAIL 
mAb (R&D Systems) after labeling the purifi  ed antibody with a protein 
labeling kit (FluoReporter Oregon Green A488; Invitrogen), according to 
the manufacturer’s instructions. Purity controls of DC populations before 
and after culture were performed by triple stainings with antibodies against 
HLA-DR FITC (BD Biosciences), BDCA-2 PE (Miltenyi Biotec), or 
CD11c PE (BD Biosciences) and CD3 PerCp, CD14 PerCp, CD19 PerCp, 
or CD56 PECy5.
After incubation with these mAbs, DCs were washed twice with ice-
cold PBS and subjected to fl  ow cytometric analysis using a fl  ow cytometer 
(FACScan).
Measurement of perforin and granzyme B in the supernatants. Super-
natants were harvested after stimulation of isolated mDCs and pDCs with 
TLR7, TLR8, or TLR7/8 agonists or vehicle control for 12 h and stored at 
−20°C. Perforin and granzyme B levels were quantifi  ed by ELISA kits (Dia-
clone Research), according to the manufacturer’s instructions. Supernatants 
of T cells stimulated with 50 ng/ml PMA (Sigma-Aldrich) and 1 μg/ml 
ionomycin (Sigma-Aldrich) for 12 h served as positive controls.
Cytotoxicity assays. The ability of DCs to exert cytotoxicity was assessed 
in a conventional 2-h europium-TDA release assay (PerkinElmer), as previ-
ously described (57), according to the manufacture’s instructions. Data were 
expressed as the percentage of cytotoxicity calculated by the following 
formula: cytotoxicity (%) = (experimental release – spontaneous release)/
(maximum release – spontaneous release) × 100.
We used the chronic myelogenous leukemia cell line K562 (provided 
by C. Wagner, Medical University of Vienna, Vienna, Austria) and the 
acute T cell leukemia cell line Jurkat (provided by P. Meraner, Medical 
  University of Vienna, Vienna, Austria) as target cells. In a 96-well plate, 
5 × 103 target cells per well were incubated with mDCs and pDCs in dif-
ferent eff  ector/target ratios (starting at 25:1) in triplicates. For inhibition of 
TRAIL- and Fas ligand–dependent lysis, 5 μg/ml of azide-free neutralizing 
anti-TRAIL (clone 75411; R&D Systems) and 5 μg/ml of anti–Fas   ligand 
(clone NOK-1; BD Biosciences), respectively, were added to eff  ector cells 
30 min before the addition of target cells. A 30-min preculture of eff  ector 
cells with 5 μg/ml of an IgG1 isotype (Sigma-Aldrich) served as negative 
control. For inhibition of the perforin-based cytotoxicity, eff  ector cells were 
treated for 120 min with 100 nM concanamycin A (Sigma-Aldrich) before tar-
get cells were added.
Online supplemental material. Fig. S1 shows that mDCs, but not 
pDCs, display CD83 in IMQ-treated BCC and that perforin/granzyme 
B–containing T cells occur in lesions of allergic contact dermatitis, but not 
IMQ-treated BCC. Fig. S2 depicts NK cell–mediated cytotoxicity. Online 
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20070021/DC1.
We thank Richard L. Miller (3M Pharmaceuticals) for providing agonists to TLR7 
and TLR8 and Drs. Dieter Maurer and Ethan Shevach for critically reading the 
manuscript. We would also like to thank Sabine Altrichter for technical advice and 
Andreas Ebner for preparing the fi  gures.
The authors have no confl  icting fi  nancial interests.
Submitted: 2 January 2007
Accepted: 9 May 2007
R  E  F  E  R  E  N  C  E  S 
 1. Weeks, C.E., and S.J. Gibson. 1994. Induction of interferon and other 
cytokines by imiquimod and its hydroxylated metabolite R-842 in hu-
man blood cells in vitro. J. Interferon Res. 14:81–85.
 2. Garland, S.M., R. Waddell, A. Mindel, I.M. Denham, and J.C. 
McCloskey. 2006. An open-label phase II pilot study investigating the 
optimal duration of imiquimod 5% cream for the treatment of external 
genital warts in women. Int. J. STD AIDS. 17:448–452.
 3. Theos, A.U., R. Cummins, N.B. Silverberg, and A.S. Paller. 2004. 
Eff  ectiveness of imiquimod cream 5% for treating childhood molluscum 
contagiosum in a double-blind, randomized pilot trial. Cutis. 74:134–
138, 141–142.
 4. Gollnick, H., C.G. Barona, R.G. Frank, T. Ruzicka, M. Megahed, V. 
Tebbs, M. Owens, and P. Stampone. 2005. Recurrence rate of superfi  -
cial basal cell carcinoma following successful treatment with imiquimod 
5% cream: interim 2-year results from an ongoing 5-year follow-up 
study in Europe. Eur. J. Dermatol. 15:374–381.
 5. Peris, K., E. Campione, T. Micantonio, G.C. Marulli, M.C. Fargnoli, 
and S. Chimenti. 2005. Imiquimod treatment of superfi  cial and nod-
ular basal cell carcinoma: 12-week open-label trial. Dermatol. Surg. 
31:318–323.
  6.  Fleming, C.J., A.M. Bryden, A. Evans, R.S. Dawe, and S.H. Ibbotson. 
2004. A pilot study of treatment of lentigo maligna with 5% imiquimod 
cream. Br. J. Dermatol. 151:485–488.
 7. Akira, S., and H. Hemmi. 2003. Recognition of pathogen-associated 
molecular patterns by TLR family. Immunol. Lett. 85:85–95.
 8. Diebold, S.S., T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa. 
2004. Innate antiviral responses by means of TLR7-mediated recogni-
tion of single-stranded RNA. Science. 303:1529–1531.
  9.  Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. 
Akira, G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specifi  c rec-
ognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 
303:1526–1529.
10. Medzhitov, R., P. Preston-Hurlburt, and C.A. Janeway Jr. 1997. A 
human homologue of the Drosophila Toll protein signals activation of 
adaptive immunity. Nature. 388:394–397.
11.  Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. 
Immunol. 4:499–511.
12. Michalopoulos, P., N. Yawalkar, M. Bronnimann, A. Kappeler, and 
L.R. Braathen. 2004. Characterization of the cellular infi  ltrate during 
successful topical treatment of lentigo maligna with imiquimod. Br. J. 
Dermatol. 151:903–906.
13.  Barnetson, R.S., A. Satchell, L. Zhuang, H.B. Slade, and G.M. Halliday. 
2004. Imiquimod induced regression of clinically diagnosed superfi  cial 
basal cell carcinoma is associated with early infi  ltration by CD4 T cells 
and dendritic cells. Clin. Exp. Dermatol. 29:639–643.
14.  Smith, K.J., S. Hamza, and H. Skelton. 2004. Topical imidazoquinoline 
therapy of cutaneous squamous cell carcinoma polarizes lymphoid and 1450  TUMORICIDAL FUNCTION OF ACTIVATED DENDRITIC CELLS | Stary et al.
monocyte/macrophage populations to a Th1 and M1 cytokine pattern. 
Clin. Exp. Dermatol. 29:505–512.
15.  Kadowaki, N., S. Ho, S. Antonenko, R.W. Malefyt, R.A. Kastelein, F. 
Bazan, and Y.J. Liu. 2001. Subsets of human dendritic cell precursors 
express diff  erent Toll-like receptors and respond to diff  erent microbial 
antigens. J. Exp. Med. 194:863–869.
16.  Jarrossay, D., G. Napolitani, M. Colonna, F. Sallusto, and A. Lanzavecchia. 
2001. Specialization and complementarity in microbial molecule re-
cognition by human myeloid and plasmacytoid dendritic cells. Eur. J. 
Immunol. 31:3388–3393.
17.  Peng, G., Z. Guo, Y. Kiniwa, K.S. Voo, W. Peng, T. Fu, D.Y. Wang, 
Y. Li, H.Y. Wang, and R.F. Wang. 2005. Toll-like receptor 8-mediated 
reversal of CD4+ regulatory T cell function. Science. 309:1380–1384.
18. Schön, M.P., M. Schön, and K.N. Klotz. 2006. The small antitumoral 
immune response modifi  er imiquimod interacts with adenosine recep-
tor signaling in a TLR7- and TLR8-independent fashion. J. Invest. 
Dermatol. 126:1338–1347.
19. Schön, M., A.B. Bong, C. Drewniok, J. Herz, C.C. Geilen, J. 
Reifenberger, B. Benninghoff, H.B. Slade, H. Gollnick, and M.P. 
Schön. 2003. Tumor-selective induction of apoptosis and the small-
molecule immune response modifi  er imiquimod. J. Natl. Cancer Inst. 
95:1138–1149.
20. Grebenova, D., K. Kuzelova, O. Fuchs, P. Halada, V. Havlicek, I. 
Marinov, and Z. Hrkal. 2004. Interferon-alpha suppresses proliferation 
of chronic myelogenous leukemia cells K562 by extending cell cycle 
S-phase without inducing apoptosis. Blood Cells Mol. Dis. 32:262–269.
21. Majewski, S., M. Marczak, B. Mlynarczyk, B. Benninghoff  , and S. 
Jablonska. 2005. Imiquimod is a strong inhibitor of tumor cell-induced 
angiogenesis. Int. J. Dermatol. 44:14–19.
22.  Li, V.W., W.W. Li, K.E. Talcott, and A.W. Zhai. 2005. Imiquimod as 
an antiangiogenic agent. J. Drugs Dermatol. 4:708–717.
23. Palamara, F., S. Meindl, M. Holcmann, P. Lührs, G. Stingl, and M. 
Sibilia. 2004. Identifi  cation and characterization of pDC-like cells in 
normal mouse skin and melanomas treated with imiquimod. J. Immunol. 
173:3051–3061.
24. Fanger, N.A., C.R. Maliszewski, K. Schooley, and T.S. Griffi   th. 
1999. Human dendritic cells mediate cellular apoptosis via tumor ne-
crosis factor–related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 
190:1155–1164.
25.  Chaperot, L., A. Blum, O. Manches, G. Lui, J. Angel, J.P. Molens, and 
J. Plumas. 2006. Virus or TLR agonists induce TRAIL-mediated cyto-
toxic activity of plasmacytoid dendritic cells. J. Immunol. 176:248–255.
26.  Tucker, S.B., J.W. Polasek, A.J. Perri, and E.A. Goldsmith. 2006. Long-
term follow-up of basal cell carcinomas treated with perilesional inter-
feron alfa 2b as monotherapy. J. Am. Acad. Dermatol. 54:1033–1038.
27.  Thyrell, L., S. Erickson, B. Zhivotovsky, K. Pokrovskaja, O. Sangfelt, J. 
Castro, S. Einhorn, and D. Grander. 2002. Mechanisms of Interferon-
alpha induced apoptosis in malignant cells. Oncogene. 21:1251–1262.
28.  Lowes, M.A., F. Chamian, M.V. Abello, J. Fuentes-Duculan, S.L. Lin, 
R. Nussbaum, I. Novitskaya, H. Carbonaro, I. Cardinale, T. Kikuchi, 
et al. 2005. Increase in TNF-alpha and inducible nitric oxide synthase-
expressing dendritic cells in psoriasis and reduction with efalizumab 
(anti-CD11a). Proc. Natl. Acad. Sci. USA. 102:19057–19062.
29. Serbina, N.V., T.P. Salazar-Mather, C.A. Biron, W.A. Kuziel, and 
E.G.P. Am. 2003. TNF/iNOS-producing dendritic cells mediate in-
nate immune defense against bacterial infection. Immunity. 19:59–70.
30. Yawalkar, N., R.E. Hunger, C. Buri, S. Schmid, F. Egli, C.U. Brand, 
C. Mueller, W.J. Pichler, and L.R. Braathen. 2001. A comparative 
study of the expression of cytotoxic proteins in allergic contact dermati-
tis and psoriasis: spongiotic skin lesions in allergic contact dermatitis are 
highly infi  ltrated by T cells expressing perforin and granzyme B. Am. J. 
Pathol. 158:803–808.
31. Zauli, G., S. Sancilio, A. Cataldi, N. Sabatini, D. Bosco, and R. Di 
Pietro. 2005. PI-3K/Akt and NF-kappaB/IkappaBalpha pathways are 
activated in Jurkat T cells in response to TRAIL treatment. J. Cell. 
Physiol. 202:900–911.
32. Kataoka, T., N. Shinohara, H. Takayama, K. Takaku, S. Kondo, S. 
Yonehara, and K. Nagai. 1996. Concanamycin A, a powerful tool 
for characterization and estimation of contribution of perforin- and 
Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 
156:3678–3686.
33. Korman, N., R. Moy, M. Ling, R. Matheson, S. Smith, S. McKane, 
and J.H. Lee. 2005. Dosing with 5% imiquimod cream 3 times per week 
for the treatment of actinic keratosis: results of two phase 3, randomized, 
double-blind, parallel-group, vehicle-controlled trials. Arch. Dermatol. 
141:467–473.
34. Nikkels, A.F., C. Pierard-Franchimont, N. Nikkels-Tassoudji, R. 
Bourguignon, and G.E. Pierard. 2005. Photodynamic therapy and imiqui-
mod immunotherapy for basal cell carcinomas. Acta Clin. Belg. 60:227–234.
35.  Dixon, A.J. 2005. Multiple superfi  cial basal cell carcinomata–topical im-
iquimod versus curette and cryotherapy. Aust. Fam. Physician. 34:49–52.
36.  Sidky, Y.A., E.C. Borden, C.E. Weeks, M.J. Reiter, J.F. Hatcher, and 
G.T. Bryan. 1992. Inhibition of murine tumor growth by an interferon-
inducing imidazoquinolinamine. Cancer Res. 52:3528–3533.
37.  Sullivan, T.P., T. Dearaujo, V. Vincek, and B. Berman. 2003. Evaluation 
of superfi  cial basal cell carcinomas after treatment with imiquimod 5% 
cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol. 
Surg. 29:1181–1186.
38. Wiley, S.R., K. Schooley, P.J. Smolak, W.S. Din, C.P. Huang, J.K. 
Nicholl, G.R. Sutherland, T.D. Smith, C. Rauch, C.A. Smith, et al. 
1995. Identifi  cation and characterization of a new member of the TNF 
family that induces apoptosis. Immunity. 3:673–682.
39. Schneider, P., M. Thome, K. Burns, J.L. Bodmer, K. Hofmann, T. 
Kataoka, N. Holler, and J. Tschopp. 1997. TRAIL receptors 1 (DR4) 
and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. 
Immunity. 7:831–836.
40.  Wang, S., and W.S. El-Deiry. 2003. TRAIL and apoptosis induction by 
TNF-family death receptors. Oncogene. 22:8628–8633.
41.  Xu, W., L. Liu, and I.G. Charles. 2002. Microencapsulated iNOS-
  expressing cells cause tumor suppression in mice. FASEB J. 16:213–215.
42.  Mocellin, S., M. Provenzano, M. Lise, D. Nitti, and C.R. Rossi. 2003. 
Increased TIA-1 gene expression in the tumor microenvironment after 
locoregional administration of tumor necrosis factor-alpha to patients 
with soft tissue limb sarcoma. Int. J. Cancer. 107:317–322.
43.  Serbina, N.V., and E.G.P. Am. 2006. Monocyte emigration from bone 
marrow during bacterial infection requires signals mediated by chemo-
kine receptor CCR2. Nat. Immunol. 7:311–317.
44. Janjic, B.M., G. Lu, A. Pimenov, T.L. Whiteside, W.J. Storkus, and 
N.L. Vujanovic. 2002. Innate direct anticancer eff  ector function of hu-
man immature dendritic cells. I. Involvement of an apoptosis-inducing 
pathway. J. Immunol. 168:1823–1830.
45.  Schmitz, M., S. Zhao, Y. Deuse, K. Schakel, R. Wehner, H. Wohner, K. 
Holig, F. Wienforth, A. Kiessling, M. Bornhauser, et al. 2005. Tumoricidal 
potential of native blood dendritic cells: direct tumor cell killing and acti-
vation of NK cell-mediated cytotoxicity. J. Immunol. 174:4127–4134.
46. Lu, G., B.M. Janjic, J. Janjic, T.L. Whiteside, W.J. Storkus, and N.L. 
Vujanovic. 2002. Innate direct anticancer eff  ector function of human 
immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), 
Fas ligand, and TNF-related apoptosis-inducing ligand. J. Immunol. 
168:1831–1839.
47. Vanderheyde, N., E. Aksoy, Z. Amraoui, P. Vandenabeele, M. 
Goldman, and F. Willems. 2001. Tumoricidal activity of monocyte-
derived dendritic cells: evidence for a caspase-8-dependent, Fas-associated 
death domain-independent mechanism. J. Immunol. 167:3565–3569.
48.  Trinite, B., C. Chauvin, H. Peche, C. Voisine, M. Heslan, and R. Josien. 
2005. Immature CD4- CD103+ rat dendritic cells induce rapid caspase-
independent apoptosis-like cell death in various tumor and nontumor cells 
and phagocytose their victims. J. Immunol. 175:2408–2417.
49.  Urosevic, M., R. Dummer, C. Conrad, M. Beyeler, E. Laine, G. Burg, 
and M. Gilliet. 2005. Disease-independent skin recruitment and activa-
tion of plasmacytoid predendritic cells following imiquimod treatment. 
J. Natl. Cancer Inst. 97:1143–1153.
50.  Sato, K., S. Hida, H. Takayanagi, T. Yokochi, N. Kayagaki, K. Takeda, 
H. Yagita, K. Okumura, N. Tanaka, T. Taniguchi, and K. Ogasawara. 
2001. Antiviral response by natural killer cells through TRAIL gene 
induction by IFN-alpha/beta. Eur. J. Immunol. 31:3138–3146.JEM VOL. 204, June 11, 2007  1451
ARTICLE
51.  Kayagaki, N., N. Yamaguchi, M. Nakayama, H. Eto, K. Okumura, and 
H. Yagita. 1999. Type I interferons (IFNs) regulate tumor necrosis factor–
related apoptosis-inducing ligand (TRAIL) expression on human T cells: 
a novel mechanism for the antitumor eff  ects of type I IFNs. J. Exp. Med. 
189:1451–1460.
52. Rissoan, M.C., T. Duhen, J.M. Bridon, N. Bendriss-Vermare, C. 
Peronne, B. de Saint Vis, F. Briere, and E.E. Bates. 2002. Subtractive 
hybridization reveals the expression of immunoglobulin-like transcript 7, 
Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid 
dendritic cells. Blood. 100:3295–3303.
53.  Santoro, A., A. Majorana, L. Roversi, F. Gentili, S. Marrelli, W. Vermi, 
E. Bardellini, P. Sapelli, and F. Facchetti. 2005. Recruitment of den-
dritic cells in oral lichen planus. J. Pathol. 205:426–434.
54.  Taieb, J., N. Chaput, C. Menard, L. Apetoh, E. Ullrich, M. Bonmort, M. 
Pequignot, N. Casares, M. Terme, C. Flament, et al. 2006. A novel dendritic 
cell subset involved in tumor immunosurveillance. Nat. Med. 12:214–219.
55.  Chan, C.W., E. Crafton, H.N. Fan, J. Flook, K. Yoshimura, M. Skarica, D. 
Brockstedt, T.W. Dubensky, M.F. Stins, L.L. Lanier, et al. 2006. Interferon-
producing killer dendritic cells provide a link between innate and adap-
tive immunity. Nat. Med. 12:207–213.
56. Stary, G., C. Bangert, G. Stingl, and T. Kopp. 2005. Dendritic cells in 
atopic dermatitis: expression of FcepsilonRI on two distinct infl  ammation-
associated subsets. Int. Arch. Allergy Immunol. 138:278–290.
57. Blomberg, K., R. Hautala, J. Lovgren, V.M. Mukkala, C. Lindqvist, 
and K. Akerman. 1996. Time-resolved fl  uorometric assay for natural 
killer activity using target cells labelled with a fl  uorescence enhancing 
ligand. J. Immunol. Methods. 193:199–206.